RacingHorse
Trusted Member
The Racing Medication and Testing Consortium (RMTC) has urged racing authorities to adopt the Out of Competition Testing and Multiple Medication Violation rules approved by the Association of Racing Commissioners International (ARCI) at its Dec. 9 board meeting in Tucson, Arizona.
The new ARCI regulations go beyond blood doping to regulate a number of other substances, including a ban of the use of anabolic steroids in training unless they are prescribed by a veterinarian. They also include strict reporting requirements for other substances, such as clenbuterol, that act as anabolic agents; and a broadly expanded prohibited substance list based upon the World Anti-Doping Agency’s Prohibited Substance list.
“The Out of Competition Testing rule is vital for ensuring the integrity of racing and the health and welfare of our equine athletes,” said RMTC Executive Director Dr. Dionne Benson. “There are a number of substances that can only be found for a limited time. Expanding out of competition testing will allow racing authorities to test for those substances and ultimately deter their use.”
The Multiple Medication Violation (MMV) system was designed to be an enhanced penalty system applied above and beyond the penalty for a single medication violation for trainers who commit multiple medication-related infractions. The RMTC helped to revise the MMV penalty system to address issues that had arisen and concerns expressed by many states where legal concerns hampered adoption. Highlights of the revision include increased discretion for stewards in determining the length of a suspension and an increasing penalty for therapeutic medication violations occurring within the same year.
Industry organizations and states that have been slow to support the National Uniform Medication Program have indicated that these revisions remove a significant obstacle to full adoption.
“The RMTC stands ready to assist racing authorities in the adoption of these regulations,” said RMTC Chair Alex Waldrop. “Adoption of these programs along with the National Uniform Medication Program in its entirety will be chief among the RMTC’s objectives for 2017.”
For additional information, visit the RMTC website at rmtcnet.com or contact Hallie Lewis, RMTC communications and development consultant, at (859) 224-2848.
Continue reading...
The new ARCI regulations go beyond blood doping to regulate a number of other substances, including a ban of the use of anabolic steroids in training unless they are prescribed by a veterinarian. They also include strict reporting requirements for other substances, such as clenbuterol, that act as anabolic agents; and a broadly expanded prohibited substance list based upon the World Anti-Doping Agency’s Prohibited Substance list.
“The Out of Competition Testing rule is vital for ensuring the integrity of racing and the health and welfare of our equine athletes,” said RMTC Executive Director Dr. Dionne Benson. “There are a number of substances that can only be found for a limited time. Expanding out of competition testing will allow racing authorities to test for those substances and ultimately deter their use.”
The Multiple Medication Violation (MMV) system was designed to be an enhanced penalty system applied above and beyond the penalty for a single medication violation for trainers who commit multiple medication-related infractions. The RMTC helped to revise the MMV penalty system to address issues that had arisen and concerns expressed by many states where legal concerns hampered adoption. Highlights of the revision include increased discretion for stewards in determining the length of a suspension and an increasing penalty for therapeutic medication violations occurring within the same year.
Industry organizations and states that have been slow to support the National Uniform Medication Program have indicated that these revisions remove a significant obstacle to full adoption.
“The RMTC stands ready to assist racing authorities in the adoption of these regulations,” said RMTC Chair Alex Waldrop. “Adoption of these programs along with the National Uniform Medication Program in its entirety will be chief among the RMTC’s objectives for 2017.”
For additional information, visit the RMTC website at rmtcnet.com or contact Hallie Lewis, RMTC communications and development consultant, at (859) 224-2848.
Continue reading...